Personalized Cancer Vaccine Corporate Milestones

Personalized Cancer Vaccine Market Top Companies and Their Offerings

Bring clarity to your Personalized Cancer Vaccine Market strategy - Buy Now.

What are the Recent Developments in the Personalized Cancer Vaccine Market?

• In August 2025, the world’s first personalized mRNA-based melanoma vaccine was launched by Russia’s Gamaleya Center, which develops a unique molecular template with the use of AI-driven analysis of tumor genetics, marking a revolutionary breakthrough in cancer treatment.
• In July 2025, NeoVaxMI, an updated formula and delivery of the NeoVax personalized cancer vaccine, providing a safe, feasible, and enhanced vaccine-specific immune response in patients with melanoma, was developed by researchers of Dana-Farber Cancer Institute.

Personalized Cancer Vaccine Market Value Chain Analysis

R&D

• The R&D of the personalized cancer vaccines focuses on utilizing AI-driven genomics sequencing and next-generation bioinformatics for rapid identification of patient-specific neoantigens.
• Key players: Moderna, BioNTech, Gritstone Bio.

Clinical Trials and Regulatory Approvals

• The safety, clinical efficacy, recurrence-free survival (RFS), immunogenicity, and progression-free survival (PFS) are evaluated in the clinical trials and regulatory approvals of the personalized cancer vaccines.
• Key players: Moderna, BioNTech, Gritstone Bio.

Formulation and Final Dosage Preparation

• The formulation involves encapsulation of patient-specific neoantigen blueprints into delivery vehicles to ensure stability and cellular uptake, where the final dosage preparation involves the preparation of personalized cancer vaccines through aseptic filling into vials for intramuscular or subcutaneous administration.
• Key players: Moderna, BioNTech, Gritstone Bio.

Packaging and Serialization

• The packaging and serialization of personalized cancer vaccines involves the use of high-security, cold-chain-compliant vials and GS1-standard 2D data matrices to ensure the correct patient-specific dose is administered.
• Key players: Moderna, BioNTech, Gritstone Bio.

Distribution to Hospitals, Pharmacies

• The highly specialized ultra-cold-chain logistics and digital needle-to-needle tracking systems are responsible for the distribution of personalized cancer vaccines to hospitals and pharmacies.
• Key players: Moderna, BioNTech, Gritstone Bio.

Patient Support and Services

• The integrated digital platforms, financial assistance programs, and dedicated nurse navigators are provided in the patient support and services of the personalized cancer vaccine.
• Key players: Moderna, BioNTech, Gritstone Bio.

Market Trends

The global personalized cancer vaccine market size was estimated at USD 4.2 billion in 2025 and is predicted to increase from USD 4.99 billion in 2026 to approximately USD 23.32 billion by 2035, expanding at a CAGR of 18.7% from 2026 to 2035. The growing cancer burden globally is increasing the adoption of personalized cancer vaccines. Growing R&D activities, expanding healthcare investments, growing technological advancements, and new vaccine launches are also enhancing the market growth.